ACADIA PHARMACEUTICALS INC
For the period ended Jun 30, 2024. Filed Aug 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 7, 2024
ACAD$18.28+10.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Revenues | ||||
| Product sales, net | $241,963 | $165,235 | $447,794 | $283,697 |
| Total revenues | 241,963 | 165,235 | 447,794 | 283,697 |
| Operating expenses | ||||
| Cost of product sales | 18,230 | 7,459 | 41,181 | 9,126 |
| Research and development | 76,233 | 58,771 | 135,912 | 127,915 |
| Selling, general and administrative | 117,063 | 95,968 | 225,054 | 197,203 |
| Total operating expenses | 211,526 | 162,198 | 402,147 | 334,244 |
| Income (loss) from operations | 30,437 | 3,037 | 45,647 | (50,547) |
| Interest income, net | 6,359 | 4,550 | 11,865 | 8,350 |
| Other income (loss) | 386 | (1,244) | 672 | 3,601 |
| Income (loss) before income taxes | 37,182 | 6,343 | 58,184 | (38,596) |
| Income tax expense | 3,793 | 5,229 | 8,240 | 3,311 |
| Net income (loss) | $33,389 | $1,114 | $49,944 | $(41,907) |
| Earnings (net loss) per share: | ||||
| Basic | $0.20 | $0.01 | $0.30 | $(0.26) |
| Diluted | $0.20 | $0.01 | $0.30 | $(0.26) |
| Weighted average common shares outstanding: | ||||
| Basic | 165,551 | 163,458 | 165,174 | 163,109 |
| Diluted | 166,174 | 165,046 | 166,391 | 163,109 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.